Skip to main content
Premium Trial:

Request an Annual Quote

More Genomics Co.s to Go Public: Exelixis, Lexicon



OUTH SAN FRANCISCO, Calif.--Two more genomics companies announced their intentions to jump on the IPO bandwagon last week.

Exelixis here has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of common stock. The model systems and comparative genomics company provides functional genomics technologies for use by the pharmaceutical, diagnostic, agricultural, and animal health industries. The offering is being made through an underwriter group led by Goldman Sachs along with Credit Suisse First Boston and SG Cowen.

Lexicon Genetics of the Woodlands, Texas, also filed its registration statement proposing an initial public offering last week. Lexicon uses its proprietary gene-trapping technology to discover novel genes and expand its OmniBank library, which contains tens of thousands of knockout mouse clones for drug discovery. The company’s internet exchange,, enables researchers to access the library and collaborate with the company to discover pharmaceutical products based on gene function knowledge. J.P. Morgan and Credit-Suisse First Boston are co-lead managers of the offering. Dain Rauscher Wessels and Punk, Zeigel are co-managers.

Filed under

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.